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When should you order a Lyme titer?
■ Evidence summary
Many Lyme disease serologic tests are
ordered inappropriately, often influenced
by patient demand. In a prospective, cross-
sectional survey of Wisconsin physicians,
only 20% of ordered tests were appropri-
ate. Tests were classified as inappropriate 
if ordered (1) for asymptomatic patients,
(2) for patients with physician-diagnosed
erythema migrans, (3) for patients receiv-
ing empiric antibiotic treatment, or (4) as
test-of-cure.3
The positive predictive value of a test
(the likelihood that a person who tests 
positive actually has the disease) depends
on the prevalence of that condition.
Available Lyme serology tests vary in their
sensitivity and specificity. Selecting patients
with signs or symptoms of disseminated
Lyme disease theoretically increases the
pretest probability, thus improving the
positive predictive value of the test.
In a prospective study of 46 treated
patients with culture-proven erythema
migrans, 91% had a positive ELISA or
immunoglobulin M (IgM) immunoblot
result at 8 to 14 days after baseline. Peak
IgM antibody levels were seen at this time
Strict use of these rules would lead to fewer 
false positives but would miss atypical forms
The use of testing as described in this article is
consistent with the recommendations of the CDC,
academic infectious disease experts, and insurance
companies. Other indications for ordering a Lyme
test include the presence of oligoarthritis, cranial
neuropathy (facial nerve palsy is most common),
heart block, or meningitis. There is significant 
controversy about testing, treatment, and even
defining late Lyme disease. The universe of people
with positive Lyme serology who have fatigue,
memory impairment, myalgias, and arthralgias far
exceeds those with erythema migrans. A quick
Google search reveals numerous patient support
groups whose mission is to support those unfortu-
nate people who believe they are afflicted with late
Lyme disease. Strict use of these lab-ordering rules
would lead to fewer false positives but also risks
missing persons with forme fruste (atypical or 
variant forms) of this disease who may benefit
from antimicrobial therapy. This is a highly contro-
versial area of medicine and the limited evidence is
conflicting. The cost of the Lyme test is not trivial,
with a reflex panel (sensitive ELISA followed by
specific Western blot) billed at over $250. 
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Lyme titers should be ordered for patients with
signs or symptoms of disseminated Lyme disease,
but who do not have the pathognomonic erythema
migrans rash (strength of recommendation [SOR]:
C, based on expert opinion). Symptomatic patients
with erythema migrans should be treated without
being tested, given the high probability of having
Lyme disease. 
Serologic testing within the first week following
potential infection is justified only if antibiotics will
be withheld and a repeat serologic study will be
performed 8 to 14 days after an initial negative test
(SOR: C, based on expert opinion).1 Testing should
be 2-tiered, including an initial highly 
sensitive test (enzyme-linked immunosorbent
assay [ELISA]) followed by a supplemental highly
specific test (Western blot) (SOR: C, based on
expert opinion and small case-control study).2
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Testing should 
be 2-tiered, with 
a highly sensitive
test (ELISA) 
followed by a
highly specific
one (Western blot)
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among patients with localized or dissemi-
nated disease. Detectable IgM levels
appeared within a few days of onset of ery-
thema migrans and were found in most
individuals with disease of at least 2 weeks
duration.4 Another small study of 55 treat-
ed patients similarly found peak antibody
response at 8 to 12 days into treatment.5
A recent review article recommends
serologic testing for patients with a moder-
ate pretest probability (ie, patients with
objective signs of Lyme disease from a
highly or moderately endemic area).
Patients from highly endemic areas who
present with erythema migrans have a high
enough pretest probability to make the
diagnosis of Lyme disease without serolog-
ic testing.6
Recommendations from others
The Centers for Disease Control and
Prevention (CDC) defines a case of Lyme
disease as physician-diagnosed erythema
migrans ≥5 cm in diameter, or at least 1
objective manifestation of late Lyme dis-
ease (eg, musculoskeletal, cardiovascular,
or neurologic symptoms) with laboratory
confirmation of Borrelia burgdorferi infec-
tion using a 2-tiered assay.7 Thus, the CDC
notes that Lyme disease is a clinical diagno-
sis and accordingly recommends against
testing patients who are asymptomatic or
who have proven disease (erythema
migrans).
The American College of Physicians
Clinical Guidelines recommend perform-
ing serologic testing for patients with an
intermediate pretest probability between
20% and 80%.8 Low pretest probability
scenarios (<20%) include patients with
nonspecific symptoms of myalgia such as
fatigue, stiffness, and diffuse muscle aches
and tenderness. High pretest probability
scenarios (>80%) include patients with
erythema migrans. Intermediate pretest
probability scenarios include patients with
possible disseminated Lyme disease find-
ings such as recurrent oligoarticular
inflammatory arthritis (TABLE). Cost effec-
tiveness analyses support this approach.9
Guidelines established by a joint
CDC/Association of State and Territorial
Public Health Laboratory Directors com-
mission require a 2-tiered laboratory
T A B L E
CLINICAL SCENARIO TEST? RATIONALE
Erythema migrans No Pretest probability high; clinical diagnosis  
of Lyme disease (treat without testing)
Signs/symptoms of disseminated Yes Pretest probability intermediate; 
Lyme disease, live in endemic region high prevalence yields high PPV
Signs/symptoms of disseminated Yes Pretest probability intermediate; cost-effective
Lyme disease, live in non-endemic
region
Nonspecific myalgias No Pretest probability too low
Asymptomatic patient No Pretest probability too low
Empiric antibiotic response; No Antibiotic treatment decreases humoral 
treatment testing not cost effective
Test-of-cure No Test remains positive after treatment
Immunized No ELISA will be positive 
(Western blot could assess exposure)
Pretest probability scenarios for suspected Lyme disease
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approach to diagnosis.2 A highly sensitive
initial test (ELISA) is followed by a highly
specific supplemental test (Western blot).
These guidelines have good clinical appli-
cability (overall sensitivity 50%, specificity
100%).10 The relatively low sensitivity is
likely due to antibiotic treatment of sever-
al subjects resulting in reduced humoral
response. 
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THE JOURNAL OF FAMILY PRACTICE uses 
a simplified rating system called the 
Strength of Recommendation Taxonomy
(SORT). More detailed information can 
be found in the February 2003 issue,
“Simplifying the language of patient care,”
pages 111–120.
Strength of Recommendation (SOR) ratings
are given for key recommendations for readers.
SORs should be based on the highest-quality 
evidence available.
A Recommendation based on consistent and 
good-quality patient–oriented evidence.
B Recommendation based on inconsistent or 
limited-quality patient-oriented evidence.
C Recommendation based on consensus, usual practice,
opinion, disease-oriented evidence, or case series for 
studies of diagnosis, treatment, prevention, or screening
Levels of evidence determine whether a study
measuring patient-oriented outcomes is of
good or limited quality, and whether the results
are consistent or inconsistent between studies.
STUDY QUALITY
1—Good-quality, patient-oriented evidence 
(eg, validated clinical decision rules, systematic reviews 
and meta-analyses of randomized controlled trials
[RCTs] with consistent results, high-quality RCTs, or
diagnostic cohort studies)
2—Lower-quality patient-oriented evidence 
(eg, unvalidated clinical decision rules, lower-quality 
clinical trials, retrospective cohort studies, case control
studies, case series)
3—Other evidence (eg, consensus guidelines, usual 
practice, opinion, case series for studies of diagnosis,
treatment, prevention, or screening)
Consistency across studies 
Consistent—Most studies found similar or at least 
coherent conclusions (coherence means that differences
are explainable); or If high-quality and up-to-date 
systematic reviews or meta-analyses exist, they support
the recommendation
Inconsistent—Considerable variation among study findings
and lack of coherence; or If high-quality and up-to-date 
systematic reviews or meta-analyses exist, they do not 
find consistent evidence in favor of the recommendation
Evidence-based medicine ratings
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